Frequency of myopathy in patients receiving
The American Journal of Cardiology(2005)
摘要
Lovastatin (Mevacor) 20 mg is being considered for nonprescription availability. Because the most severe untoward consequence of therapy with any statin is rhabdomyolysis, the clinical data for lovastatin pertaining to this adverse event were reviewed. Evidence to date, based on almost 2 decades Of experience, points to an extremely low risk for myopathy and rhabdomyolysis associated with lovastatin. (c) 2005 by Excerpta Medica Inc.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要